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Abstract
The methods of nasal absorption (NA) and bronchial absorption (BA) use synthetic absorptive matrices (SAM) to absorb the mucosal lining
fluid (MLF) of the human respiratory tract. NA is a non-invasive technique which absorbs fluid from the inferior turbinate, and causes minimal
discomfort. NA has yielded reproducible results with the ability to frequently repeat sampling of the upper airway.
By comparison, alternative methods of sampling the respiratory mucosa, such as nasopharyngeal aspiration (NPA) and conventional swabbing,
are more invasive and may result in greater data variability. Other methods have limitations, for instance, biopsies and bronchial procedures are
invasive, sputum contains many dead and dying cells and requires liquefaction, exhaled breath condensate (EBC) contains water and saliva, and
lavage samples are dilute and variable.
BA can be performed through the working channel of a bronchoscope in clinic. Sampling is well tolerated and can be conducted at multiple sites
in the airway. BA results in MLF samples being less dilute than bronchoalveolar lavage (BAL) samples.
This article demonstrates the techniques of NA and BA, as well as the laboratory processing of the resulting samples, which can be tailored
to the desired downstream biomarker being measured. These absorption techniques are useful alternatives to the conventional sampling
techniques used in clinical respiratory research.
Video Link
The video component of this article can be found at https://www.jove.com/video/56413/
Introduction
Most respiratory diseases cause an inflammatory response, and there is an urgent need for sampling from the respiratory mucosal surface in
allergic rhinitis, viral and fungal infections, tuberculosis, asthma, chronic obstructive pulmonary disease, pulmonary fibrosis and lung cancer 1.
Nasopharyngeal aspirate (NPA), nasal lavage, and bronchoalveolar lavage (BAL) are common techniques for sampling the upper and lower
airway. However, these techniques present considerable problems including poor tolerability, dilution of inflammatory mediators, and the inability
to frequently repeat sampling2. One alternative to NPA sampling is the use of swabs, either nylon flocked, cotton, or rayon3,4, but these also have
limitations, since they cause discomfort and damage to the nasal epithelium, and in some cases irreversible binding of inflammatory mediators5.
These techniques cannot generally be repeated serially over an hour, and alternative techniques may be more effective for detection of low
abundance cytokines and chemokines5,6. Additionally, the user variability associated with these techniques may generate inconsistencies in data,
resulting in the requirement of larger patient cohorts.
Alternatively, absorption techniques using both natural and synthetic sponges have been used to collect MLF from mucosal surfaces. Ophthalmic
sponges composed of natural cellulose (e.g., Weck-cel) have been used to sample saliva, cervical, and vaginal secretions7. In addition, synthetic
sponges made from polyvinyl alcohol (PVA) and hydroxylated polyvinyl acetate (HPVA) have been utilised8. Seven different absorptive materials
have been compared for sampling oral fluid prior to measuring antibodies9, while polyurethane mini-sponges have been used to collect human
tears10.
Filter paper consisting of natural cellulose from the cotton plant has been widely used to absorb nasal secretions since the pioneering paper
of Alam and colleagues in 199211,12,13,14,15,16,17. Filter paper discs have been produced from filter cards (e.g. Shandon), and have been
utilized to measure histamines and cytokines after controlled nasal allergen challenges and with natural allergen exposure18,19,20,21. However,
different batches of filter paper vary in their degree of protein binding and some fail to release cytokines. Methods using a synthetic absorptive
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matrix (SAM) have therefore been developed2,22,23. SAMs are now generally used to obtain nasal MLF by NA. These absorbent materials are
comfortable to use and can obtain MLF even from inflamed noses at frequent intervals over extended periods of time.
Nasal absorption is a form of Precision Mucosal Sampling using a SAM for the sampling of MLF in the upper airway. NA devices are
manufactured as CE-marked medical devices from medical grade materials using clean rooms and are free of dust and allergens. The NA
sampler consists of a handle and SAM in a sterile cryotube. The SAM consists of polymers, typically fibers, but it is also available as foam,
and these are selected to be soft and absorptive, with rapid wicking for sample collection. SAMs have minimal protein binding to allow the
efficient elution of absorbed secretions. NA is a very gentle, non-invasive technique that can be performed on donors of all ages. In addition,
serial sampling, even every few minutes, is possible. NA has been validated against existing upper airway sampling techniques5 and repetitive
sampling has allowed generation of kinetic data following challenge of the airway with allergen23,24,25, bacterial endotoxin26 and viral-type TLR
agonists (Jha, A. et al., manuscript in preparation). NA has also been used in infants to investigate the natural history of atopy27,28,29 and in viral
bronchiolitis30.
Bronchoscopic microsampling (BMS) is a procedure for collection of MLF in the lower airway that has been developed by Olympus31,32,33.
Unfortunately, this BMS system is only licensed in Japan. Olympus supply two BMS systems: one with a fibrous hydroxylated polyester (FHPE)
probe34,35,36,37, and one with a cotton probe33,38,39,40,41,42,43. A major stumbling block has been that the BMS probe used in patients with asthma
caused mucosal contact bleeding, with half of all samples contaminated with blood. The authors concluded that it was not feasible to sample
MLF using this BMS system from peripheral airways in asthma patients43.
As an alternative, we have developed BA using a soft SAM that can be performed during bronchoscopic investigation of the lower airways,
including following experimental infection of asthmatic subjects with rhinovirus6. The BA device consists of: an external hollow catheter, a hand-
piece that on activation extrudes the SAM, and a central plastic guide wire that has the SAM on its end. As for NA, BA kits are manufactured
from medical grade materials using clean rooms and are free of dust and allergens. Additionally, devices are CE marked and are provided
gamma-irradiated. The SAM strip is soft, absorptive, and has rapid wicking for sample collection. It also has minimal protein binding to allow
the efficient elution of absorbed secretions. The device can fit through the working channel of a bronchoscope and can be used to rapidly and
accurately sample MLF at specific sites of interest within the airway. Unlike BAL or BMS, BA does not result in contact bleeding or additional
patient discomfort post-procedure.
Careful consideration should be given to the processing of NA and BA samples. Samples can be directly frozen and processed in batches, or
can be processed immediately. The type of processing can be tailored toward certain downstream applications, including immunoassays for
cytokines, chemokines and immunoglobulins, or elutions of viral, bacterial, and host cell associated RNA. We present the clinical collection and
laboratory processing techniques associated with NA and BA as a guide for clinical researchers.
Protocol
The techniques used in the following protocol have been approved by the West London Research Ethics Committee (Reference number 15/
lO/0444).
1. Nasal Absorption (NA)
1. Preparation prior to NA sampling
1. When carrying out NA, first wash hands and put on gloves, preferably in front of the patient.
2. Inspect the nasal cavity using a head torch, and have the clinician use their non-dominant thumb to retract the patient's nose to
visualize the nasal cavity.
 
Note: A nasal speculum is not usually required.
3. Visualize the nasal cavity and inferior turbinate prior to sampling.
 
Note: The nares (nostrils) are not round in cross-section and they go straight backwards. Generally, the inferior turbinate can be
seen as a bulge or indentation on the lateral wall of the nostril, with the nasal septum forming the smooth, flat medial wall. We want to
sample from this inferior turbinate, since the underlying epithelium is a simple ciliated epithelium of the respiratory tract44.
2. NA sampling
1. When sampling, pass the NA SAM gently up the lumen of the nostril, orientating it to be flat against the inferior turbinate.
2. Ask the donor to use an index finger to press the SAM onto the nasal mucosa. NA can cause a slight tickling, with possible eye
watering, as the MLF is absorbed.
 
Note: In adults, we generally perform NA for 60 s.
3. After absorption of MLF, remove the NA device from the nostril and put back into the original tube.
4. Process the samples immediately in the laboratory or freeze them, as detailed later in this protocol.
 
Note: NA is being studied in a variety of nasal mucosal challenge models, and also in different airways diseases. However, validation
against other respiratory sampling methods should be performed for each study and patient population.
2. Bronchial Absorption (BA)
1. Preparation prior to BA sampling
 
Note: BA is performed by specialized personnel in a bronchoscopy suite.
1. Before placing the BA device down the catheter, check that the SAM is extruding and withdrawing back into the catheter.
2. Prior to conducting BA on a patient, conduct a mock BA on a bronchoscopy simulator.
2. BA sampling
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1. Pass the bronchoscope down the trachea and right main bronchus to the level of the bronchus intermedius, just proximal to the division
into the right lower and right middle lobes.
 
NOTE: We typically sample from the bronchus intermedius, though other sites within the airway can be sampled. When observing the
catheter and SAM, one cannot see the bronchoscope tip. We observe the following simple steps for BA, once the bronchoscope has
reached the desired sampling site.
2. CATHETER DOWN: Insert the BA catheter through the operating channel of the bronchoscope until the white tip is just visible in the
airway, to a maximum of 1 cm distal to the end of the bronchoscope. Keep the bronchoscope and catheter tip in the center of the lumen
of the airway. Be careful to minimize contact between the catheter tip and the bronchial mucosa to reduce the risk of abrasion to the
mucosa.
3. SAM OUT: Depress the handle of the BA device so that the SAM is extruded into the lumen of the right middle or right lower lobe
airway. Under direct vision, bend the tip of the bronchoscope to ensure that the SAM is making contact with the MLF on the airway wall.
Leave the SAM within the airway, flat to the mucosal wall for 30 s.
4. SAM IN: Look through the bronchoscope to ensure that the moist SAM probe is straight and not bent back over the end of the catheter.
If required, the catheter and bronchoscope tip can be brought back to straighten the SAM. Under direct vision, retract the straight SAM
gently back into the catheter.
 
NOTE: If there is difficulty retracting the SAM back into the catheter, withdraw the whole device with SAM extruded back out of the
airway.
5. CATHETER UP: Withdraw the entire catheter from the operating channel of the bronchoscope.
6. CUT OFF SAM: The SAM is cut off with sterile scissors and is then put into a cryotube on ice. These samples can be processed with
varying methods, as detailed later in this protocol.
3. Processing of NA and BA Samples
Note: There are numerous options for laboratory processing of samples resulting from NA and BA. These protocols seek to store samples for
later use, and to elute the MLF sample from the SAM.
1. Options for immediate handling of NA and BA samples
1. Option 1: Store the moist SAM on ice for a few hours prior to further processing.
2. Option 2: Immediately deep freeze NA SAMs in the collection tube. Similarly, freeze BA SAMs in cryogenic vials after removal, with
scissors, from the sampling device.
3. Option 3: Place the detached SAM in elution buffer (300 µL) prior to processing directly or deep freezing.
2. Options of elution buffer for NA and BA samples
 
Note: The choice of elution buffer depends on what is going to be analyzed in the MLF sample and we suggest four main alternatives:
1. Use a pre-prepared assay buffer suitable for immunoassay procedures. Such buffers should contain a small amount of detergent
(0.05%) as well as protein, e.g., bovine serum albumin (BSA) at 1%.
2. Alternatively, use a buffer containing a greater amount of detergent, so that cell lysis occurs.
 
Note: We use buffers containing Triton-X or NP40 at 1% concentration. Cell lysis buffers enable both intracellular and extracellular
cytokines to be eluted from the SAM, and generally result in higher levels of cytokines and chemokines. These buffers should also
contain protein, and are made up with BSA to 1%.
3. For RNA measurements, such as quantitative PCR of viral RNA or measuring host RNA, add RNA extraction buffer directly to the moist
SAM.
 
Note: Chaotropic RNA extraction buffers contain guanidinium that denatures proteins. An alternative is to add RNA extraction buffer to
the eluted MLF fluid contained in immunoassay or cell lysis buffer.
4. Use organic solvents, such as trifluoroacetic acid, for extraction of lipids and metabolites, for evaluation by mass-spectrometry.
 
Note: Details of all these reagents are included in the Materials section.
3. Elution technique
1. For any of the above elution techniques, insert the SAM into a 2 mL micro-centrifuge tube, along with the desired extraction buffer.
2. Vortex mix the sample for 30 s to wash the SAM of loosely attached fluids and biomolecules.
3. To ensure full sample recovery, perform centrifugal elution by adding the moist SAM to a spin filter mini-column that inserts into the
same 2 mL micro-centrifuge tube used for washing.
 
Note: Two types of spin filter mini-column can be used. The first contains only a plastic mesh, which holds the SAM in place, allowing
full elution of fluids. Alternatively, if working with infectious materials, use spin filters with a 0.22 µm pore size. These filters will sterilize
samples and are suitable for samples with suspected Mycobacterial infection. However, these filters should be pre-incubated with
buffer, to minimize binding of mediators to the filter by non-specific interactions.
4. Use sterilized forceps to transfer the moist SAM to the spin filter. Change forceps between samples to prevent contamination.
5. Centrifuge samples for 20 min at 16,000 x g in a mini-centrifuge cooled to 4 °C.
4. Summary example protocol
1. In the laboratory, label 2 mL micro-centrifuge tubes for sample collection and add the desired volume of elution buffer (typically 300 µL
for NA; 100 µL for BA). Seal lid and place on ice.
2. Following sampling (either immediately or in the lab) the SAM is removed from the handle using forceps and placed into the buffer
containing collection tube (produced in previous step). Ensure the cap of the microcentrifuge tube is closed securely and transfer the
samples, on ice, to the laboratory for further processing.
3. Remove tubes containing SAM and elution buffer from their transfer container and vortex mix for 30 s.
4. Using sterile forceps, remove SAM and place into a spin column (with or without 0.22 µm cellulose acetate filter).
5. Collect the elution buffer from the collection tube and retain.
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6. Place the spin column, with SAM, in the original collection tube (or a new one if sterile-filtering samples) and add collection buffer to
spin column. In this manner, the wash fluid will pass through the spin column back into the collection tube, helping to elute the sample
from the SAM.
7. Centrifuge the samples with lids sealed (16,000 x g, 20 min, 4 °C).
8. Remove the samples from the centrifuge and place into a rack.
9. Open the sealed lid of the tubes and remove the spin column containing the SAM. Dispose of SAM and spin column in an appropriate
waste container.
10. Carefully aliquot the eluate contained within the tube into labelled cryogenic tubes. Record the total volume of eluate and the volume in
each aliquot.
11. Transfer the sealed cryogenic tubes to a -80°C freezer and store upright until use. 
Representative Results
NA has been utilized in a number of studies to easily and non-invasively measure mucosal inflammation. Following administration of allergen
to the nose, prostaglandin-D2 (PGD2) levels can be observed to rise and fall within minutes (Figure 1), in line with mast cell degranulation
(Thwaites et al., manuscript in preparation). Additionally, mediators of type-II inflammation, such as IL-5 (Figure 2, reprinted with permission from
24), can be measured in the hours following nasal allergen challenge23,24. In experimental infection of allergic asthmatics and healthy controls, NA
was used to measure a panel of mediators, including interferon-gamma (IFN-γ), over the course of 7 days (Figure 3, reprinted with permission
from 6). Additionally, in natural respiratory syncytial virus (RSV) infection of infants, NA demonstrated RSV to be associated with elevated levels
of inflammatory cytokines, such as IFN-γ, relative to non-RSV infants with bronchiolitis and healthy controls (Figure 4, reprinted with permission
from 30). Interestingly, this discrimination between RSV and non-RSV bronchiolitis was not significant in time-matched NPA samples (Figure 4).
BA was also used during experimental infection of allergic asthmatics with rhinovirus. At day 4 of rhinovirus infection, levels of IFN-γ, CXCL11,
IL-10, and IL-5 were elevated from baseline (Figure 5; A, B, C and D, respectively). Additionally, this technique demonstrated elevated IL-5
levels in the lower airway of allergic asthmatics during rhinovirus infection, relative to healthy controls (Figure 5D)(Figure 5 reprinted with
permission from 6).
These representative results were generated from samples eluted using assay buffer containing 0.05% Tween-20 and 1% BSA (see Table of
Materials).
 
Figure 1: Rapid generation and clearance of prostaglandin-D2 following nasal allergen challenge. Levels of prostaglandin-D2 (PGD2)
measured from nasal absorption eluates in serial samples following nasal allergen challenge with Timothy grass pollen (n=5). Each line
represents data from one individual. Please click here to view a larger version of this figure.
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Figure 2: Kinetic measurement of IL-5 following nasal allergen challenge. Production of IL-5 in serial nasal absorption samples following
nasal allergen challenge. Three repeat allergen challenge studies were conducted, with the participants (n=19) receiving placebo (blue), low
dose (10 mg) oral prednisone (orange), or high dose (25 mg) oral prednisone (red) one hour prior to allergen administration. Lines denote
geometric mean and error bars are 95% confidence intervals of all participants. (Figure reprinted with permission from Leaker et al., Mucosal
Immunology, 2017). Please click here to view a larger version of this figure.
 
Figure 3: Induction of Interferon-γ during rhinovirus infection. During infection challenge of healthy adults (n= 11, blue) and allergic
asthmatics (n= 28, red) with rhinovirus-16, nasal absorption sampling was used to measure levels of interferon-γ (IFN- γ). Data are represented
as A) raw spaghetti plots of individuals and B) median levels with error bars denoting interquartile ranges. (Figure reprinted with permission from
Hansel et al.6). Please click here to view a larger version of this figure.
 
Figure 4: Nasosorption discriminates elevated Interferon-γ associated with RSV infection of infants. Nasal absorption and
nasopharyngeal aspiration (NPA) were used to measure interferon-γ levels in infants with bronchiolitis associated with respiratory syncytial
virus (RSV) infection (red, n=12), a non-RSV respiratory pathogen (green, n=12), and healthy controls (blue, n=9). Data were analyzed using a
Kruskall-Wallis test with Dunns correction for multiple comparisons (***p<0.001). Lines denotes median values and error bars are interquartile
ranges. (Figure modified with permission from Thwaites et al.30). Please click here to view a larger version of this figure.
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Figure 5: Inflammatory mediators in bronchial absorption samples during rhinovirus infection.
 
Following rhinovirus-16 infection of healthy controls (n=10, blue) and allergic asthmatic volunteers (n=23, red), bronchial absorption was used to
measure levels of A) IFN-γ, B) CXCL11, C) IL-10, and D) IL-5 at baseline and on day 4 of infection. Data analyzed by Wilcoxon signed rank test
(matched samples) and Mann-Whitney test (unmatched samples). Figure reprinted with permission from Hansel et al.6 Please click here to view
a larger version of this figure.
Discussion
Results from existing airway sampling techniques are regarded as highly variable; alternative sampling techniques are needed to standardize
research within this field5. NA and BA permit sampling of MLF in a non-invasive manner, and have exciting potential to measure immune
responses in healthy and diseased airways. These techniques offer numerous potential advantages over existing techniques, including greater
tolerability, speed of sampling, the ability to frequently repeat sampling, lower inter-user variability, and decreased dilution of immune mediators5.
The duration of absorption and the processing technique used should be optimized for each study and rigorously maintained between sampling
events. Additionally, in the case of BA, the site of sampling within the airway should be carefully replicated between individuals.
NA, and particularly BA, are still relatively novel techniques for clinical research. However, the benefits of these techniques have resulted in their
use in numerous studies, including careful validation against alternative techniques5. These devices are now available as CE-marked devices
ready for widespread use in respiratory research. While NA and BA result in much smaller sample volumes than alternative sampling techniques,
higher obtained concentrations can result in greater sensitivity for low abundance immune mediators.
Depending on desired downstream applications, NA and BA samples can be directly frozen for later processing, enhancing study feasibility in a
clinical research environment. The protocol for sample handling can also be adapted to suit particular downstream applications. The suggested
processing techniques can be used for collection of protein or lipid immune mediators or nucleic acids, but should be optimized for each study.
In particular, MLF can be eluted with different buffers. Firstly, immunoassay buffer can be used to measure mucosal cytokines, chemokines,
and antibodies6,45. Buffers with higher detergent levels can also be used to guarantee cell lysis occurs, allowing the inclusion of intra-cellular
cytokines. Chaotropic RNA extraction buffers should be used for the determination of viral infection, viral load, host mRNA, and the microbiome.
Alternatively, organic solvents can be used for lipidomics and mass spectrometry.
In conclusion, direct absorption of MLF from mucosal surfaces is an exciting technique with potential use in respiratory, gastro-intestinal,
urogenital, and other mucosal diseases. However, these promising absorption techniques will require precise validation of sampling and
processing technique for individual assays (biomarkers) in each disease setting. In addition, these novel precision mucosal sampling techniques
will require validation against conventional samples, such as from blood, breath, and sputum. With these techniques, MLF can be used to
measure microbes, cytokines, chemokines, prostanoids, and antibodies.
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